Document is current
Any future updates will be listed below
-
Authors
Umeshappa, Channakeshava Sokke https://orcid.org/0000-0002-9867-2141
Solé, Patricia
Yamanouchi, Jun
Mohapatra, Saswat https://orcid.org/0000-0002-7430-7289
Surewaard, Bas G. J.
Garnica, Josep https://orcid.org/0000-0001-9493-1321
Singha, Santiswarup
Mondal, Debajyoti
Cortés-Vicente, Elena
D’Mello, Charlotte
Mason, Andrew
Kubes, Paul https://orcid.org/0000-0002-2835-4244
Serra, Pau
Yang, Yang
Santamaria, Pere https://orcid.org/0000-0003-3469-1586
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
- License Information
-
More Information
Article History
Received: 2 June 2021
Accepted: 17 May 2022
First Online: 7 June 2022
Competing interests
: P.Santamaria is founder, scientific officer and stockholder of Parvus Therapeutics. He is inventor on patents on pMHC-based nanomedicines and receives funding from the company. The remaining authors declare no competing interests.
